13:45 - 14:00 Opening & Welcome

• Introduction & About EHA
  C Dufour (Italy)

14:00 - 16:00 Session 1: Specific Diseases - Granulocyte disorders

Chairs: E Papadaki (Greece) & J Palmblad (Sweden)

• Neutropenia in infancy: Definition, diagnosis/overlap and treatment
  F Fioredda (Italy)
• Typology of Infections in ELANE patients: a window to understand the consequences of phagocytes defect
  J Donadieu (France)
• Congenital Neutropenias across life: From infancy to young adults: Follow up, pregnancy, transformation to MDS/AML
  K Welte (Germany)
• Neutropenia in adult and elderly: How we diagnose benign and neutropenias preceding MDS/AML
  E Papadaki (Greece)
• Mechanisms of drug-induced Neutropenias: Genetic predisposition and differential diagnosis
  J Palmblad (Sweden)

16:00 - 16:30 Coffee break

16:30 - 17:00 Oral Session 1

• INCREASED FREQUENCY OF THE ETHNIC NEUTROPENIA-ASSOCIATED RS2814778 SNP OF DUFFY ANTIGEN RECEPTOR FOR CHEMOKINES (DARC) GENE IN A COHORT OF EUROPEAN PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
  E Papadaki (Greece)
• A CASE OF LEUKOCYTE ADHESION DEFICIENCY TYPE III SUCCESSFULLY TREATED WITH HAPLOIDENTICAL STEM CELL TRANSPLANTATION
  S Kim (South Korea)

17:00 - 18:15 Session 2: Leukemia predisposing diseases

Chairs: C Mecucci (Italy) & B Schlegelberger (Germany)

• How I diagnose and manage leukemia predisposition in children
  C Niemeyer (Germany)
• How I diagnose and manage leukemia predisposition in adults
  B Schlegelberger (Germany)
• New approaches in understanding Leukemia predisposition
  T Ripperger (Germany)

18:15 - 18:45 Oral Session 2

• GERMLINE JAK2 V617F MUTATION IS A SUSCEPTIBILITY GENE CAUSE FIRST-DEGREE RELATIVE WITH MYELOPROLIFERATIVE NEOPLASM
  HS Park (South Korea)
• INFANTILE LEUKEMIA: WHAT EXACTLY THE FACTORS THAT DETERMINE ITS DISTINCT BIOLOGICAL NATURE? CLINICOPATHOLOGICAL STUDY OF 78 CASES
  E Wang (USA)

18:45 - 19:45 Welcome reception

08:45 - 10:15 Session 3: Specific Diseases - Telomere diseases and Fanconi Anemia

Chair: C Dufour (Italy)

• Telomere disease: Molecular pathogenesis & clinical phenotype
  I Dokal (United Kingdom)
• Gene therapy in Fanconi anemia (FA)
  J Bueren (Spain)
• Non classical Constitutional Marrow Failure Syndromes
  M Miano (Italy)
• Best abstract: INCREASED PROPORTION OF INTERMEDIATE AND NON-CLASSICAL MONOCYTES IN THE PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC IDIOPATHIC NEUTROPENIA
  N Bizymi (Greece)

10:15 - 10:45 Coffee break

10:45 - 11:45 Session 4: Specific Diseases - Ribosomal disorders

Chairs: K de Keersmaecker (Belgium) & A Warren (United Kingdom)

• Shwachman-Diamond Syndrome and the quality control of Ribosome assembly
  A Warren (United Kingdom)
• Zebrafish models and hematologic Ribosome diseases
  B Payne (United Kingdom)
• Disruption of pre-rRNA maturation in DBA
  PE Gleizes (France)

11:45 - 12:15 Session 5: Presentation and discussion of rare and unusual cases

Chairs: C Mecucci (Italy) & B Schlegelberger (Germany)

• Presentation and discussion of rare and unusual cases
  C Mecucci (Italy), C Niemeyer (Germany), T Ripperger (Germany), B Schlegelberger (Germany) & selected abstracts.

12:15 - 13:15 Lunch

13:15 - 13:45 Oral Session 3

• NEXT-GENERATION SEQUENCING REVEALS NOVEL GERMLINE ALTERATIONS OF DDX41 IN 3 PATIENTS DIAGNOSED WITH MYELOID NEOPLASMS
  C Andrés Zayas (Spain0
• SAMD9 AND SAMD9L IN MYELOID MALIGNANCIES AND BONE MARROW FAILURE SYNDROME
  J Cammenga (Sweden)

13:45 - 15:00 Session 6: Round table I - SCT when and how in:

• Severe Congenital Neutropenia (SCN)
  J Donadieu (France)
• Telomere diseases
  F Fioredda (Italy)
• Ribosome diseases
  JH Dalle (France)
• Fanconi Anemia
  C Dufour (Italy)
• Forum discussion
  All speakers

15:00 - 15:30 Coffee Break

15:30 - 16:30 Oral Session 4

• STUDY OF PROINFLAMMATORY AND ANTI-INFLAMMATORY STATES IN MYELODYSPLASTIC SYNDROME PATIENTS
  A Efat (Egypt)
• RESULTS OF USE OF ARRAY CGH TO IDENTIFY GENETIC BACKGROUND OF FANCONI ANEMIA
  A Repzynska (Poland)
• DYSREGULATION OF MIR‐125B PREDICTS POOR RESPONSE TO THERAPY IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA
  S Abd Moghny (Egypt)
• PROGNOSTIC CATEGORIZATION OF AML PATIENTS BASED ON CD7 AND CD56 EXPRESSION-A TERTIARY CARE CENTER STUDY IN NORTHERN INDIA
  S Rai (India)

16:30 - 17:30 Session 7: Round table II - Is precision medicine applicable to Granulocytes & constitutional MFS?

• The lesson learned from MDS
  Speaker to be announced
• Severe Congenital Neutropenia (SCN)
  I Touw (The Netherlands)
• Fanconi Anemia
  T Leblanc (France)
• Forum discussion
  All speakers

09:00 - 10:00 Session 8: Other stakeholders

• Patient Associations - The voice of the patients German FA parent Association
  R Dietrich (Germany)
• Drugs for rare diseases - The companies' view
  Speaker to be announced
• Evidence based medicine in rare diseases from the regulators’ view
  Speaker to be announced

10:00 - 10:30 Oral Session 5

• CLINICAL AND BIOLOGICAL FEATURES OF SECONDARY AUTOIMMUNE NEUTROPENIA: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
  P Farruggia (Italy)
• PATIENTS AFFECTED BY GAUCHER DISEASE SHOW IMMUNE-DYSREGULATION FEATURES SECONDARY TO A DEFECT OF APOPTOSIS
  G Guardo (Italy)

10:30 - 11:00 Coffee break

11:00 - 12:15 Session 9: The Future Networking & New therapies

• New Frontiers in Diagnosis and Treatment of Gaucher's Disease
  M Machaczka (Sweden)
• Networking
  E Papadaki (Greece)
• CRISPR/CAS9 mediated Elane Knockout Enables Neutrophilic Maturation of HSPCS and IPSCS of Severe Congenital Neutropenia Patients
  J Skokowa (Germany)

12:15 - 12:30 Closing ceremony

• Closing remarks
  C Dufour (Italy)

12:30 - 13:30 Farewell lunch